Study of the Effectiveness and the Tolerance of Intraprostatic A-botulinic Toxin Injection, in the Treatment of Symptomatic Benign Prostate Hypertrophy.
Phase of Trial: Phase III
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Botulinum toxin A (Primary) ; Alpha 1 adrenergic receptor antagonists; Cholestenone 5-alpha reductase inhibitors; Herbal medicines
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- Acronyms PROTOX
- 24 Apr 2013 Planned end date changed from 1 Jun 2013 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
- 21 Jan 2011 New trial record